Author: Rodrigues, João F. S. ; França, Lucas M. ; Lima, João L. do Carmo ; Fernandes, Fernanda K. M. ; Monteiro-Neto, Valério ; Saminez, Warlison F. de Silva ; Soczek, Suzany H. S. ; Pontes, Jaqueline P. ; Soley, Bruna da Silva ; Fernandes, Elizabeth S. ; Paes, Antônio M. A. ; Pinto, Bruno A. S. ; Santos, Gabriela S. ; Maria-Ferreira, Daniele ; Araújo, Mizael C. ; Quintão, Nara L. M.

Sugar-induced metabolic imbalances are a major health problem since an excessive consumption of saccharides has been linked to greater obesity rates at a global level. Sucrose, a disaccharide composed of 50% glucose and 50% fructose, is commonly used in the food industry and found in a range of fast, restaurant, and processed foods. Herein, we investigated the effects of a TRPC4/TRPC5 blocker, ML204, in the metabolic imbalances triggered by early exposure to sucrose-enriched diet in mice. TRPC4 and TRPC5 belong to the family of non-selective Ca+2 channels known as transient receptor potential channels. High-sucrose (HS)-fed animals with hyperglycaemia and dyslipidaemia, were accompanied by increased body mass index. mesenteric adipose tissue accumulation with larger diameter cells and hepatic steatosis in comparison to those fed normal diet. HS mice also exhibited enhanced adipose, liver, and pancreas TNFα and VEGF levels. ML204 exacerbated hyperglycaemia, dyslipidaemia, fat tissue deposition, hepatic steatosis, and adipose tissue and liver TNFα in HS-fed mice. Normal mice treated with the blocker had greater hepatic steatosis and adipose tissue cell numbers/diameter than those receiving vehicle, but showed no significant changes in tissue inflammation, glucose, and lipid levels. The results indicate that TRPC4/TRPC5 protect against the metabolic imbalances caused by HS ingestion.

100 Deals associated with TRPC4/TRPC5 inhibitors(University of Chinese Academy of Sciences)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anxiety Disorders	Preclinical	China	University of Chinese Academy of Sciences	07 Feb 2025
Anxiety Disorders	Preclinical	China	China Pharmaceutical University	07 Feb 2025
Depressive Disorder	Preclinical	China	China Pharmaceutical University	07 Feb 2025
Depressive Disorder	Preclinical	China	University of Chinese Academy of Sciences	07 Feb 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

TRPC4/TRPC5 inhibitors(University of Chinese Academy of Sciences)

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation